In a nutshell: Haematological immune‐related adverse events
Summary The use of immune checkpoint inhibitors (ICIs) have transformed oncological care. In this ‘nutshell review’, we summarize the most common haematological immune‐related adverse events (irAEs) associated with checkpoint inhibitors. We also outline management strategies and address current evidence regarding ICI rechallenge.
Authors
- Jodi V. Mones (ORCID: https://orcid.org/0000-0002-1327-775X)
- Rebecca Karp Leaf (ORCID: https://orcid.org/0000-0002-9978-8779)
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Global Cancer Institute (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2026-08-24
- DOI
- https://doi.org/10.1111/bjh.70782
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00